Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (10): 1089-1094.doi: 10.11958/20240256
• Clinical Research • Previous Articles Next Articles
YANG Hu1(), LEI Jun2, YANG Li2, PENG Xiaotong1,△(
)
Received:
2024-03-02
Revised:
2024-04-08
Published:
2024-10-15
Online:
2024-10-14
Contact:
△ E-mail:YANG Hu, LEI Jun, YANG Li, PENG Xiaotong. Clinical characteristics and risk prediction model construction of children with Kawasaki disease complicated with pleural effusion[J]. Tianjin Medical Journal, 2024, 52(10): 1089-1094.
CLC Number:
组别 | n | 完全性KD | IVIG无应答 | 病原学阳性 | 冠脉病变 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KD对照组 | 118 | 105(89.0) | 6(5.1) | 28(23.7) | 11(9.3) | |||||||||||||||||
KD-PE组 | 11 | 9(81.8) | 2(18.2) | 4(36.4) | 2(18.2) | |||||||||||||||||
χ2 | 0.047 | 2.967 | 0.317 | 0.168 | ||||||||||||||||||
组别 | WBC/(×109/L) | NEU/% | LYM/% | |||||||||||||||||||
KD对照组 | 15.5±5.7 | 67.5(54.3,73.4) | 21.9(17.5,33.3) | |||||||||||||||||||
KD-PE组 | 18.7±6.1 | 83.3(75.4,86.3) | 12.0(8.1,19.1) | |||||||||||||||||||
t或Z | 1.748 | 3.500** | 3.277** | |||||||||||||||||||
组别 | Hb/(g/L) | HCT/% | PLT/(×109/L) | |||||||||||||||||||
KD对照组 | 110(103,116) | 32.1(30.1,33.4) | 389.0(280.0,464.0) | |||||||||||||||||||
KD-PE组 | 104(98,115) | 31.8(28.1,33.6) | 310.0(226.0,426.0) | |||||||||||||||||||
Z | 0.709 | 1.000 | 1.324 | |||||||||||||||||||
组别 | PCT/(ng/mL) | ESR/(mm/1 h) | CRP/(mg/L) | |||||||||||||||||||
KD对照组 | 0.3(0.2,1.0) | 63.9(46.0,82.9) | 41.3(23.1,49.9) | |||||||||||||||||||
KD-PE组 | 1.2(0.6,4.3) | 85.4(60.8,100.9) | 127.2(97.2,172.1) | |||||||||||||||||||
Z | 3.244** | 2.320* | 4.512** | |||||||||||||||||||
组别 | ALT/(U/L) | AST/(U/L) | ALB/(g/L) | |||||||||||||||||||
KD对照组 | 33.2(19.6,78.1) | 35.7(25.1,50.0) | 40.1(37.0,42.3) | |||||||||||||||||||
KD-PE组 | 138.6(46.7,173.5) | 126.4(58.1,147.0) | 32.6(24.8,34.4) | |||||||||||||||||||
Z | 2.564* | 3.779** | 4.526** | |||||||||||||||||||
组别 | GLB/(g/L) | Na+/(mmol/L) | D-dimer/(mg/L) | |||||||||||||||||||
KD对照组 | 21.8(19.7,26.4) | 135.0(133.5,136.0) | 1.3(0.6,2.2) | |||||||||||||||||||
KD-PE组 | 22.4(19.8,27.9) | 135.0(133.0,135.3) | 2.1(0.8,3.6) | |||||||||||||||||||
Z | 0.194 | 1.101 | 1.852 | |||||||||||||||||||
组别 | LDH/(U/L) | CK-MB/(U/L) | IgG/(g/L) | |||||||||||||||||||
KD对照组 | 315.0(273.2,343.9) | 16.0(12.0,22.0) | 6.8(4.6,9.5) | |||||||||||||||||||
KD-PE组 | 310.3(262.8,374.2) | 18.0(10.0,19.0) | 5.7(4.8,8.8) | |||||||||||||||||||
Z | 0.261 | 0.211 | 0.135 |
Tab.1 Comparison of clinical data between the KD-PE group and the control group
组别 | n | 完全性KD | IVIG无应答 | 病原学阳性 | 冠脉病变 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KD对照组 | 118 | 105(89.0) | 6(5.1) | 28(23.7) | 11(9.3) | |||||||||||||||||
KD-PE组 | 11 | 9(81.8) | 2(18.2) | 4(36.4) | 2(18.2) | |||||||||||||||||
χ2 | 0.047 | 2.967 | 0.317 | 0.168 | ||||||||||||||||||
组别 | WBC/(×109/L) | NEU/% | LYM/% | |||||||||||||||||||
KD对照组 | 15.5±5.7 | 67.5(54.3,73.4) | 21.9(17.5,33.3) | |||||||||||||||||||
KD-PE组 | 18.7±6.1 | 83.3(75.4,86.3) | 12.0(8.1,19.1) | |||||||||||||||||||
t或Z | 1.748 | 3.500** | 3.277** | |||||||||||||||||||
组别 | Hb/(g/L) | HCT/% | PLT/(×109/L) | |||||||||||||||||||
KD对照组 | 110(103,116) | 32.1(30.1,33.4) | 389.0(280.0,464.0) | |||||||||||||||||||
KD-PE组 | 104(98,115) | 31.8(28.1,33.6) | 310.0(226.0,426.0) | |||||||||||||||||||
Z | 0.709 | 1.000 | 1.324 | |||||||||||||||||||
组别 | PCT/(ng/mL) | ESR/(mm/1 h) | CRP/(mg/L) | |||||||||||||||||||
KD对照组 | 0.3(0.2,1.0) | 63.9(46.0,82.9) | 41.3(23.1,49.9) | |||||||||||||||||||
KD-PE组 | 1.2(0.6,4.3) | 85.4(60.8,100.9) | 127.2(97.2,172.1) | |||||||||||||||||||
Z | 3.244** | 2.320* | 4.512** | |||||||||||||||||||
组别 | ALT/(U/L) | AST/(U/L) | ALB/(g/L) | |||||||||||||||||||
KD对照组 | 33.2(19.6,78.1) | 35.7(25.1,50.0) | 40.1(37.0,42.3) | |||||||||||||||||||
KD-PE组 | 138.6(46.7,173.5) | 126.4(58.1,147.0) | 32.6(24.8,34.4) | |||||||||||||||||||
Z | 2.564* | 3.779** | 4.526** | |||||||||||||||||||
组别 | GLB/(g/L) | Na+/(mmol/L) | D-dimer/(mg/L) | |||||||||||||||||||
KD对照组 | 21.8(19.7,26.4) | 135.0(133.5,136.0) | 1.3(0.6,2.2) | |||||||||||||||||||
KD-PE组 | 22.4(19.8,27.9) | 135.0(133.0,135.3) | 2.1(0.8,3.6) | |||||||||||||||||||
Z | 0.194 | 1.101 | 1.852 | |||||||||||||||||||
组别 | LDH/(U/L) | CK-MB/(U/L) | IgG/(g/L) | |||||||||||||||||||
KD对照组 | 315.0(273.2,343.9) | 16.0(12.0,22.0) | 6.8(4.6,9.5) | |||||||||||||||||||
KD-PE组 | 310.3(262.8,374.2) | 18.0(10.0,19.0) | 5.7(4.8,8.8) | |||||||||||||||||||
Z | 0.261 | 0.211 | 0.135 |
指标 | β | SE | Wald χ2 | P | OR | OR 95%CI |
---|---|---|---|---|---|---|
NEU | 0.047 | 0.056 | 0.699 | 0.403 | 1.048 | 0.939~1.169 |
LYM | -0.098 | 0.096 | 1.051 | 0.305 | 0.906 | 0.751~1.094 |
CRP | 0.044 | 0.018 | 6.217 | 0.013 | 1.045 | 1.009~1.082 |
ESR | 0.006 | 0.021 | 0.096 | 0.756 | 1.006 | 0.967~1.048 |
ALB | -0.281 | 0.125 | 5.070 | 0.024 | 0.755 | 0.591~0.964 |
常数项 | 2.221 | 7.165 | 0.096 | 0.757 | 9.217 |
Tab.2 Multivariate Logistic regression analysis of risk factors for KD complicated with PE
指标 | β | SE | Wald χ2 | P | OR | OR 95%CI |
---|---|---|---|---|---|---|
NEU | 0.047 | 0.056 | 0.699 | 0.403 | 1.048 | 0.939~1.169 |
LYM | -0.098 | 0.096 | 1.051 | 0.305 | 0.906 | 0.751~1.094 |
CRP | 0.044 | 0.018 | 6.217 | 0.013 | 1.045 | 1.009~1.082 |
ESR | 0.006 | 0.021 | 0.096 | 0.756 | 1.006 | 0.967~1.048 |
ALB | -0.281 | 0.125 | 5.070 | 0.024 | 0.755 | 0.591~0.964 |
常数项 | 2.221 | 7.165 | 0.096 | 0.757 | 9.217 |
[1] | MCCRINDLE B W, ROWLEY A H, NEWBURGER J W, et al. Diagnosis,treatment,and long-term management of kawasaki disease:a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17):e927-e999. doi:10.1161/CIR.0000000000000484. |
[2] | VERVOORT D, DONNÉ M, VAN GYSEL D. Pitfalls in the diagnosis and management of Kawasaki disease:An update for the pediatric dermatologist[J]. Pediatr Dermatol, 2018, 35(6):743-747. doi:10.1111/pde.13620. |
[3] | 胡亚美, 江载芳, 申昆玲, 等. 诸福棠实用儿科学[M]. 8版. 北京: 人民卫生出版社, 2015:783. |
HU Y M, JIANG Z F, SHEN K L, et al. Zhu Futang Practical Pediatrics[M]. 8th ed. Beijing: People's Medical Publishing House, 2015:783. | |
[4] | 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会风湿学组, 中华医学会儿科学分会免疫学组, 等. 川崎病诊断和急性期治疗专家共识[J]. 中华儿科杂志, 2022, 60(1):6-13. |
Subspecialty Group of Cardiology,the Society of Pediatrics, Chinese Medical Association,Subspecialty Group of Rheumatology,the Society of Pediatrics, Chinese Medical Association,Subspecialty Group of Immunology,the Society of Pediatrics,Chinese Medical Association, et al. The expert consensus on diagnosis and acute-phase treatment of Kawasaki disease[J]. Chinese Journal of Pediatrics, 2022, 60(1):6-13. doi:10.3760/cma.j.cn112140-20211018-00879. | |
[5] | CHIANG W N, HUANG P Y, KUO H C, et al. Evaluation of formosa score and diagnostic sensitivity and specificity of four asian risk scores for predicting intravenous immunoglobulin resistance in Kawasaki disease:a bivariate Meta-analysis[J]. Front Cardiovasc Med, 2023, 10:1164530. doi:10.3389/fcvm.2023.1164530. |
[6] | HE T, YANG Z, WANG X, et al. Kawasaki disease associated pulmonary involvement in infants[J]. Pediatr Pulmonol, 2021, 56(10):3389-3394. doi:10.1002/ppul.25596. |
[7] | ALGHAMDI L, ALZAHRANI A, ALGHAMDI F A, et al. A challenging diagnosis of Kawasaki disease shock syndrome complicated by bilateral pleural effusion:a case report and literature review[J]. Cureus, 2023, 15(11):e49671. doi:10.7759/cureus.49671. |
[8] | ARSLANOGLU AYDIN E, DEMIR S, AYDIN O, et al. Pleural effusion as an atypical presentation of Kawasaki disease:a case report and review of the literature[J]. J Med Case Rep, 2019, 13(1):344. doi:10.1186/s13256-019-2284-4. |
[9] | ALHAMMADI A H, HENDAUS M A. Comorbidity of Kawasaki disease and group a streptococcal pleural effusion in a healthy child:a case report[J]. Int J Gen Med, 2013, 6:613-616. doi:10.2147/IJGM.S49510. |
[10] | LEE S H, JEON Y H, YANG H J, et al. Pleural effusion and disseminated intravascular coagulopathy:the rarely reported complications of Kawasaki disease[J]. Clin Pediatr(Phila), 2010, 49(6):598-600. doi:10.1177/0009922809356468. |
[11] | TANG Y, YAN W, SUN L, et al. Kawasaki disease associated with mycoplasma pneumoniae[J]. Ital J Pediatr, 2016, 42(1):83. doi:10.1186/s13052-016-0292-1. |
[12] | KHOURY L, LIVNAT G, HAMAD SAIED M, et al. Pneumonia in the presentation of Kawasaki disease:the syndrome or a sequence of two diseases?[J]. Clin Case Rep, 2022, 10(12):e6676. doi:10.1002/ccr3.6676. |
[13] | SINGH S, GUPTA A, JINDAL A K, et al. Pulmonary presentation of Kawasaki disease-a diagnostic challenge[J]. Pediatr Pulmonol, 2018, 53(1):103-107. doi:10.1002/ppul.23885. |
[14] | 中华医学会呼吸病学分会胸膜与纵隔疾病学组筹. 胸腔积液诊断的中国专家共识[J]. 中华结核和呼吸杂志, 2022, 45(11):1080-1096. |
Pleural and Mediastinal Diseases Working Group Preparatory of Chinese Thoracic Society. Chinese expert consensus on diagnosis of pleural effusion[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2022, 45(11):1080-1096. doi:10.3760/cma.j.cn112147-20220511-00403. | |
[15] | CAO X S, ZHENG W Q, HU Z D. Diagnostic value of soluble biomarkers for parapneumonic pleural effusion[J]. Crit Rev Clin Lab Sci, 2023, 60(3):233-247. doi:10.1080/10408363.2022.2158779. |
[16] | KOGAN Y, SABO E, ODEH M. Role of C-reactive protein in discrimination between transudative and exudative pleural effusions[J]. Diagnostics (Basel), 2021, 11(11):2003. doi:10.3390/diagnostics11112003. |
[17] | RISMANTAB O, MOOSAVI S, FARAHNAK M R, et al. Role of CRP as a marker for discrimination of exudative and transudative pleural effusion[J]. Monaldi Arch Chest Dis, 2022, 92(4):2059. doi:10.4081/monaldi.2022.2059. |
[18] | 黄晓碧, 赵胜, 郑丽云, 等, 急性时相反应蛋白SAA和CRP对川崎病静脉注射免疫球蛋白无应答的预测价值[J]. 天津医药, 2023, 51(3):299-303. |
HUANG X B, ZHAO S, ZHENG L Y, et al. Predictive value of acute phase proteins SAA and CRP in non-response to intravenous immunoglobulin in kawasaki disease[J]. Tianjin Med J, 2023, 51(3):299-303. doi:10.11958/20221011. | |
[19] | MAMMADOV G, LIU H H, CHEN W X, et al. Hepatic dysfunction secondary to Kawasaki disease:characteristics,etiology and predictive role in coronary artery abnormalities[J]. Clin Exp Med, 2020, 20(1):21-30. doi:10.1007/s10238-019-00596-1. |
[20] | HUA W, MA F, WANG Y, et al. A new scoring system to predict Kawasaki disease with coronary artery lesions[J]. Clin Rheumatol, 2019, 38(4):1099-1107. doi:10.1007/s10067-018-4393-7. |
[21] | WANG J, HUANG X, GUO D. Predictors and a novel predictive model for intravascular immunoglobulin resistance in Kawasaki disease[J]. Ital J Pediatr, 2023, 49(1):126. doi:10.1186/s13052-023-01531-7. |
[1] | WANG Yuanzhen, WEI Hongyan, CHANG Lixian, ZHANG Yingyuan, LIU Chunyun, LIU Li. Establishment and validation of a risk prediction model for primary liver cancer complicated with pulmonary infection before intervention [J]. Tianjin Medical Journal, 2024, 52(9): 940-945. |
[2] | GUO Zhenjiang, ZHAO Guangyuan, DU Liqiang, LIU Fangzhen. Development and validation of a preoperative nomogram predictive model for proximal gastric cancer with microscopic positive margin [J]. Tianjin Medical Journal, 2024, 52(8): 845-849. |
[3] | LYU Mengna, LI Jianbin, WU Rui. Early predictors of the severity of COVID-19 in patients with autoinflammatory diseases [J]. Tianjin Medical Journal, 2024, 52(5): 528-531. |
[4] | ZHENG Kangpeng, TANG Xinguo, XU Qi, FAN Yuting, LIANG Bo, FU Xiaowei, FANG Lu. Nomogram construction and validation for predicting the possibility successful implementation of radical surgery in gallbladder cancer patients [J]. Tianjin Medical Journal, 2024, 52(5): 536-540. |
[5] | ZHU Yongyi, WEN Bolun, WU Qinglin, LIANG Shaoling, ZONG Yindong. Effect of dexmedetomidine on shivering and hemodynamics during spinal anesthesia in pregnant and postpartum women [J]. Tianjin Medical Journal, 2024, 52(4): 387-390. |
[6] | DU Fengjiao, DU Boping, JIA Hongyan, XING Aiying, LI Zihui, ZHU Chuanzhi, LI Hua. Study on the value of screening cytokines in pleural effusion by liquid array technology in the diagnosis of tuberculous pleurisy [J]. Tianjin Medical Journal, 2024, 52(3): 319-323. |
[7] | GAO Guangren, FENG Lianrong, FU Jinguo, GUO Run, NIU Heping, LI Fengpeng, ZHANG Qianyu, ZHANG Jun. Characteristics of myocardial injury in patients with acute myocardial infarction complicated with pleural effusion and its influence on long-term prognosis [J]. Tianjin Medical Journal, 2024, 52(2): 197-200. |
[8] | YU Ping, ZHOU Min, SU Dan. Construction and validation of chemotherapy resistance prediction model for ovarian cancer [J]. Tianjin Medical Journal, 2024, 52(11): 1177-1182. |
[9] | LIANG Yaobing, FU Zhenhua, ZHAO Ziyue, LUO Jianming, CHENG Dongyu, JIANG Haixing, QIN Shanyu. Risk factors and prediction model of acute respiratory failure in patients with hypertriglyceridemic acute pancreatitis [J]. Tianjin Medical Journal, 2024, 52(11): 1183-1187. |
[10] | GU Yunyun, ZHONG Chongming, YANG Haiyan. Predictive value of uric acid/albumin ratio for coronary heart disease in patients with chronic kidney disease [J]. Tianjin Medical Journal, 2024, 52(11): 1202-1206. |
[11] | YANG Yuanyuan, WANG Ziyun, ZHOU Zhong. Influencing factors and prognostic value of ESR, hs-CRP, IL-6 and D-D in patients with tuberculous polyserous effusion [J]. Tianjin Medical Journal, 2023, 51(6): 628-632. |
[12] | YAO Kunmei, XIA Zhonghua, HUANG Xingjie, HUANG Min, LIU Qiong, ZHOU Hanli. The clinical significance of serum levels of GDF-15 and hs-CRP in patients with coronary slow flow [J]. Tianjin Medical Journal, 2023, 51(4): 418-421. |
[13] | HUANG Xiaobi, ZHAO Sheng, ZHENG Liyun, QI Xiaohui. Predictive value of acute phase proteins SAA and CRP in non-response to intravenous immunoglobulin in Kawasaki disease [J]. Tianjin Medical Journal, 2023, 51(3): 299-302. |
[14] | GUO Zhenjiang, ZHAO Guangyuan, DU Liqiang, LIU Fangzhen. Establishment and validation of a predictive nomogram model for advanced gastric cancer with lymphovascular invasion [J]. Tianjin Medical Journal, 2023, 51(12): 1382-1386. |
[15] | MA Mengxue, MA Ping, XU Qingbin, ZHANG Shichang. Construction and verification of risk prediction model for acute myocardial infarction with heart failure [J]. Tianjin Medical Journal, 2023, 51(11): 1221-1226. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||